Comprehensive Safety & Toxicology Services

Southern Research develops and manages nonclinical safety and pharmacokinetic studies to help our clients understand margins of safety and to bring novel therapeutics to the clinic.


Your Gateway to Nonclinical Toxicology Expertise

Our toxicologists have decades of experience in the safety testing of small molecules, biologics, and novel therapeutics for the treatment of cancer. Vaccine safety and mRNA therapeutics have also been a major focus at Southern Research since the COVID-19 pandemic. Our team also have extensive experience with vectored vaccines and oncolytic viruses to treat cancer.

Our clinical pathology, immunology and in-vitro capabilities allow us to measure effects on the immune system by flow cytometry as well as anti-drug antibodies by ELISA, mRNA levels by PCR, and blood cytokine levels by Luminex and Mesoscale Discovery.

Our internal partnership with our Infectious Disease Department allows us to conduct efficacy and toxicity studies under biosafety level 3 containment. We have worked with government agencies to test novel vaccine delivery technologies, such as microneedle array patches and the reproductive safety of drugs and plant-derived dietary supplements. We offer standard PK, dose range-finding, and repeat dose GLP studies in small and large animal models, as well as biodistribution and neurovirulence testing of vaccines. Standard routes of administration include dermal, oral, intravenous, intradermal, intramuscular, intracranial, intranasal, intrathecal, and subcutaneous.

Our Toxicology Services

General Toxicology

IND-Enabling Services

Genetic Toxicology


Safety Toxicology

Specialized Toxicology

SEND Datasets

Revealing the Nonclinical Safety Profile

Unwavering Commitment to Quality and Client Satisfaction

Our toxicology studies and IND-enabling programs are tailored to the type of molecule being developed, relevant regulatory guidance, and with the planned clinical treatment regimen in mind. We help our clients de-risk their molecules and understand FDA and EMA feedback related to the next stage of drug development.

FDA and ICH guidance documents and GLP regulations provide directive on the design and conduct of toxicology studies at our AALAC accredited animal facility. Our board-certified veterinary pathologists put their findings in context of overall health and our historical control database. Clients come to Southern Research for a customer-focused experience where knowledge and quality meet operational excellence.

Our Toxicology Experts

Joseph Randall, Ph.D.

Director of Toxicology

Erin Luea

Senior Scientist

Partner With Us

Let us be your trusted partner in navigating the complexities of preclinical toxicology research. Our comprehensive preclinical toxicology services, combined with our unwavering commitment to quality and client satisfaction, make us the ideal partner for ensuring the safety of your products, streamlining regulatory submissions, and building a reputation for quality and reliability.

Contact us today to discuss your specific nonclinical toxicology needs and embark on a journey towards safer products, healthier lives, and a brighter future.

Southern Research News

Southern Research awards biotech funds, bringing new jobs and business to Alabama

June 28, 2024

June 27, 2024, Birmingham, Ala – Southern Research has awarded more than $2.7 million in funds to eight biotech companies through a fund established as a result of the Innovate Alabama Tax Credit.
Read More

Southern Research Selects Chief Operating Officer

May 9, 2024

May 8, 2024 Birmingham, Ala. – Harry C. Ledebur, Jr., Ph.D., is joining Southern Research as Chief Operating Officer, bringing to the role more than 25 years of experience across the pharmaceutical, biotechnology, and contract-research industry. In his new position at Southern ...
Read More

Southern Research Awarded Grant to Develop Novel Antidotes for Arsenical Poisoning

April 11, 2024

Project Aims to Deliver Safer and More Effective Treatments for Cutaneous Injuries Southern Research is pleased to announce the award of a UG3/UH3 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (N...
Read More